<DOC>
	<DOCNO>NCT00724451</DOCNO>
	<brief_summary>The goal study elucidate reason patient chronic hepatitis C ( CHC ) would consider eligible antiviral treatment . The study conduct common clinical practice approximately 54 site Italy . Patients deem eligible antiviral therapy treat discretion physician either peginterferon alfa-2a peginterferon alfa-2b , combination ribavirin , accordance approve labeling . A secondary objective study define `` treatment failure '' evaluate reason treatment discontinuation .</brief_summary>
	<brief_title>Observational Study Assessing Chronic Hepatitis C Management Clinical Practice Italy ( Study P05488 AM1 )</brief_title>
	<detailed_description>Probability sampling : Consecutive adult patient chronic hepatitis C clinical practice approximately 54 site Italy include study . The decision treatment choice fall discretion treat physician .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Willingness sign Informed Consent Male female patient &gt; =18 year age Chronic Hepatitis C Not previously treat PegInterferons Positive serum hepatitis C virus ( HCV ) ribonucleic acid ( RNA ) Previous treatment peginterferon Participation therapeutic Good Clinical Practice ( GCP ) clinical study within 30 day prior study start</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>